Efficacy and safety of hepatic artery infusion chemotherapy with mFOLFOX in primary liver cancer patients with hyperbilirubinemia and ineffective drainage: a retrospective cohort study

BACKGROUND: Hyperbilirubinemia is a major barrier to anti-tumor treatment in patients with end-stage primary liver cancer. However, no research has demonstrated the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) in primary liver cancer patients with hyperbilirubinemia. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tianxiao, Dong, Jiahong, Zhang, Yuewei, Ren, Zhizhong, Liu, Ying, Yang, Xiaowei, Sun, Dawei, Wang, Yaqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073781/
https://www.ncbi.nlm.nih.gov/pubmed/35530940
http://dx.doi.org/10.21037/atm-22-978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073781/
https://www.ncbi.nlm.nih.gov/pubmed/35530940
http://dx.doi.org/10.21037/atm-22-978

Ejemplares similares